Browse our anti-SPARC (SPARC) Antibodies

Human Secreted Protein, Acidic, Cysteine-Rich (Osteonectin) (SPARC) interaction partners

1. A significant relation was found between SPARC rs3210714 and rs7719521, and immunohistochemical expression of VEGF (P = 0.046 and P = 0.027, respectively). SPARC rs7719521 showed a significant association with Nottingham Prognostic Index (NPI) (P = 0.032). The present study revealed that SPARC rs3210714 and rs7719521 polymorphisms are associated with breast cancer risk and its prognosis.

2. SPARC knockdown partially eliminated TGFB1 function in inducing EMT of A549 cells. SPARC follistatin-like functional domain reduced the expression of E-cadherin, but had no effect on the expression of p-Akt and p-ERK

3. there is a significant difference in serum osteonectin concentration and tumor size in pancreatic adenocarcinoma.

4. The data provided evidence that DNA methylation in SPARC gene may play a role in the progression of T-cell non-Hodgkin's lymphoma (T-NHL).

5. Hepatic SPARC expression is associated with liver injury and fibrogenic processes in non-alcoholic fatty liver disease.

6. Plasma samples from lung cancer patients and healthy heavy-smokers controls were tested for levels of COL11A1 and COL10A1 (n = 57 each) and SPARC (n = 90 each). Higher plasma levels of COL10A1 were detected in patients (p

7. The authors have confirmed the presence of SPARC expression in melanoma, Kaposi sarcomas (KS), leiomyosarcomas (LMS) and angiosarcomas (AS) and also detected it for the first time in atypical fibroxanthomas (AFX).

8. Results revealed that hypermethylation of the SPARC promoter was the primary mechanism of SPARC downregulation in prostate cancer. SPARC expression was frequently lost during the promoter hypermethylation but could be restored by 5-Aza-Cdr.

9. Stromal SPARC expression was a useful biomarker for predicting prognosis in patients with resected pancreatic ductal adenocarcinoma.

10. SPARC is closely related to the development of breast cancer and can be used as a tumor marker for breast cancer recurrence.

11. SPARC expression was inversely associated with the degree of malignancy and it had a negative correlation with VEGF-C and VEGF-D expression. Results suggest SPARC might function as a tumor suppressor inhibiting angiogenesis and lymphangiogenesis in ovarian cancer by reducing the expression of VEGF-C and VEGF-D.

12. SPARC may be involved in gastric cancer metastasis by effecting on tumor microenvironment

13. SPARC treatment enhances the epithelial mesenchymal transition signaling pathway via activation of AKT, and exogenous SPARC and tumor expressing SPARC might be associated with tumor progression in head and neck cancers.

14. The epicardial adipose tissue expresses the mRNA of osteopontin, osteoprotegerin, and osteonectin genes that have been implicated in the calcification process; such expression is statistically associated with some components of HDL subclasses in coronary artery disease patients.

15. detection of SPARC mRNA and protein expression levels may facilitate early diagnosis and prognosis assessment of esophageal squamous cell carcinoma.

16. SPARC rs17718347 and rs2347128 single nucleotide polymorphisms are associated with progression-free survival in locally advanced and metastatic pancreatic cancer patients.

17. results demonstrated that loss of miR-211 expression and thus uncontrolled SPARC overexpression might drive progression of hepatocellular carcinoma (HCC), which may provide a novel therapeutic strategy for the treatment of HCC.

18. Data suggest that plasma SPARC levels may be biomarker for vascular complications among Chinese type 2 diabetic patients; patients in lowest SPARC tertile have increased odds of aortic stiffness but reduced odds of peripheral arterial disease.

19. The profiled circulating tumour cells also expressed elevated levels of stem cell markers, and the extracellular matrix protein, SPARC. The expression of SPARC might correspond to an epithelial-mesenchymal transition in pancreatic circulating tumour cells

20. Data suggest that both osteonectin and FGF21 levels in serum are associated with early nephropathy in type 2 diabetes, albeit with different patterns; persistent hyperglycemia may inhibit bone formation leading to osteoporosis. (FGF21 = fibroblast growth factor 21)

Mouse (Murine) Secreted Protein, Acidic, Cysteine-Rich (Osteonectin) (SPARC) interaction partners

1. The application of the combined siRNAs of SPARC, CCR2, and SMAD3 genes ameliorated inflammation and fibrosis in bleomycin-induced mice. It systemically reinstated multiple biopathways, probably through controlling on different cell types including fibroblasts, monocytes/macrophages, endothelial cells and others.

2. It is a matricellular glycol that regulates cell proliferation, tissue repair, and tumorigenesis and a potential therapeutic target for conditions involving intestinal inflammation.

3. Sparc levels in tendons are critical for proper collagen fibril maturation.

4. miR-29 directly targeted SPARC, resulting in degradation of SPARC-encoding mRNA and reduction in the SPARC protein level.

5. SPARC plays a crucial role in the proliferation and differentiation of C2C12 and may be involved in the link between the ECM remodeling and mitochondrial func

6. SPARC is regulating the interplay between myeloid-derived suppressor cells and the extracellular matrix to drive the induction of epithelial-to-mesenchymal transition in tumor cells.

7. The results demonstrate for the first time a functional role of the N-propeptide in regulating collagen fiber assembly and cell behavior and suggest that SPARC and the N-propeptide of collagen I have distinct activities in regulating collagen fiber assembly and fibroblast function.

8. SPARC plays a key role in influencing the spatial organization of the anterior segment, potentially via modulation of collagen properties, while Hevin is not likely to be involved.

9. An ADAMTS1 blocking antibody suppressed the SPARC-induced collagen I secretion, indicating that SPARC promoted collagen production directly through ADAMTS1 interaction. In conclusion, ADAMTS1 is an important mediator of SPARC-regulated cardiac aging.

10. SPARC appears to be an important modulator of the actin cytoskeleton, implicating maintenance of muscular function

11. resistivity measurements were taken on 22 mice, 11 wild-type and 11 sparc-/- (knock out for the protein SPARC: secreted protein acidic and rich in cysteine), bearing mammary carcinomas.

12. SPARC isoforms, acting on Adipose stromal cells through distinct mechanisms, have an additive effect in inducing ASC migration.

13. SPARC levels were not associated with efficacy in patients with MPC. This exploratory analysis does not support making treatment decisions regarding nab-paclitaxel plus gemcitabine or gemcitabine alone in MPC based on SPARC expression.

14. SPARC is proposed to act as a critical regulator of transglutaminase activity on collagen I with implications for mechanical strength of tissues.

15. Tumor-produced SPARC and VCAM1 are regulators of cancer extravasation.

16. The results of this study indicated that the loss of p53 by deletion/mutation in the early stages of glioma formation may cooperate with the induction of SPARC to potentiate cancer cell survival and escape from immune surveillance.

17. This work suggests that SPARC could affect anxiety-related behavior by modulating neuronal activity, and that depression-related behavior is dependent upon the adult expression of SPARC, which affects adult brain function.

18. SPARC has a significant role in the development of concanavalin A -induced severe liver injury.

19. SPARC acts as an important mediator of age-related cardiac inflammation by increasing the expression of macrophage M1 markers and decreasing M2 markers.

20. SPARC inhibits growth factor-induced signaling in both INS-1 beta cells and primary mouse islets, and inhibits IGF-1-induced proliferation of INS-1 beta cells.

Cow (Bovine) Secreted Protein, Acidic, Cysteine-Rich (Osteonectin) (SPARC) interaction partners

1. findings indicate that secreted protein acidic cysteine-rich (SPARC) is intricately regulated by pro-angiogenic and other growth factors together with components of the extracellular matrix during the follicle-luteal transition

2. This study reports the temporal changes in vascular endothelial growth factor A (VEGFA), fibroblast growth factor 2 (FGF2) and osteonectin during the follicular-luteal transition and corpus luteum development in the cow.

Zebrafish Secreted Protein, Acidic, Cysteine-Rich (Osteonectin) (SPARC) interaction partners

1. these data identify a contributory role for DNA methylation in regulating sparc expression in zebrafish embryogenesis.

2. Results establish a role for an ECM protein (Sparc) as an important regulator of embryonic haematopoiesis during early development in zebrafish.

3. Data show that Sparc (Osteonectin) functions in morphogenesis of the pharyngeal skeleton and inner ear in zebrafish.

4. Sparc is directly required for normal otolith growth

Horse (Equine) Secreted Protein, Acidic, Cysteine-Rich (Osteonectin) (SPARC) interaction partners

1. data suggest that SPARC might modulate angiogenesis during wound healing in the horse, which could protect against the disproportionate fibroplasia commonly afflicting limb wounds and leading to the development of exuberant granulation tissue

Xenopus laevis Secreted Protein, Acidic, Cysteine-Rich (Osteonectin) (SPARC) interaction partners

1. Data suggest a critical requirement for SPARC during post-gastrula development in Xenopus embryos and that SPARC, directly or indirectly, promotes cell-cell adhesion in vivo.